The availability of robotic assistance could make laparoscopic pancreaticoduodenectomy safely feasible. We herein provide a systematic review on laparoscopic robot-assisted pancreaticoduodenectomy (RAPD). Methods: Literature search was conducted on multiple databases considering articles published in English up to October 31, 2014, reporting on ten or more patients. Results: A total of 262 articles were identified. Excluding duplicates (n=172), studies not matching inclusion criteria (n=77), and studies not suitable for other reasons (n=6), a total of seven studies reporting on 312 RAPDs were eventually reviewed. These studies were either retrospective cohort studies (n=4) or case-matched studies (n=3). No randomized controlled trial was identified. Most patients undergoing RAPD were diagnosed with malignant tumors (224/312; 71.8%). RAPD was feasible in most patients. Conversion to open surgery was reported in 9.2% of the patients. A hybrid RAPD technique, employing standard laparoscopy or open surgery through a mini-incision, was adopted in most patients (178/312; 57.0%). Overall, there were six postoperative deaths at 30 days (6/312; 1.9%), including one intraoperative death caused by portal vein injury, while 137 out of 260 patients with complete information developed postoperative complications (52.7%). The mean length of hospital stay ranged from 10-29 days. Postoperative pancreatic fistula (POPF) occurred in 66 patients (66/312; 21.1%). Grade C POPF was reported in eight patients (8/312; 2.5%). The costs of RAPD were assessed in two studies, demonstrating additional costs ranging from 4,000-5,000 US dollars to 6, 193 Euro. The mean number of examined lymph nodes and the rate of positive surgical margins indicate that RAPD could be an appropriate oncologic operation. Conclusion: RAPD is safely feasible. These results were obtained in selected patients and in specialized centers. RAPD should not be implemented in the occasional patient by surgeons without advanced laparoscopic skills and formal training in robotic surgery.
Introduction
First described in 1994 by Gagner and Pomp, 1 laparoscopic pancreaticoduodenectomy (PD) is eventually gaining momentum in specialized centers. 2 The intrinsic limitations of conventional laparoscopy, the lack of standardized training in advanced laparoscopy for the earlier generations of pancreatic surgeons, and the technical challenges of PD are among the major factors that have limited the acceptance of laparoscopic PD. The enhanced dexterity offered by the da Vinci surgical system (dVss) (Intuitive Surgical, Sunnyvale, California, USA) offers the unique opportunity to verify if the well-known advantages of laparoscopy can be experienced also by patients undergoing PD. 
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Further, the use of the dVss could allow a greater proportion of pancreatic surgeons to safely pursue minimally invasive PD, since robotic surgery is more intuitive than conventional laparoscopy. 4 We herein provide a systematic review on robot-assisted PD (RAPD).
Methods
Definition of RAPD
For the purpose of this review, all procedures in which the dVss was used to perform a PD were defined as RAPD. This definition includes patients in whom the operation was carried out entirely under robotic assistance and patients in whom robotic assistance was limited to specific steps of the operation. The latter instance actually represents a hybrid procedure in which the use of robotic assistance is mixed with traditional laparoscopy and/or with traditional surgery carried out through a mini-laparotomy incision. There are several prototypes of "hybrid RAPD": 1. Laparoscopy is used for dissection and robotic assistance for digestive reconstruction. 5 2. Laparoscopy is used for preliminary dissection and robotic assistance for dissection of the posterior margin/ uncinate process and for digestive reconstructions. 6 3. Following robotic dissection, digestive reconstruction is entirely or partially carried out through a mini-laparotomy incision. 7 
Search methodology
The literature search focused solely on articles published, between January 1, 2000 and October 31, 2014, in peerreviewed journals and in English. Studies were identified by searching multiple literature databases, including Scopus, Web of Science, and PubMed using the following keywords: "pancreaticoduodenectomy and robot*," "pancreatoduodenectomy and robot*," and "duodenopancreatectomy and robot*." Queries were limited to clinical studies. Hand searches of reference lists of relevant literature reviews were also performed.
Selection of studies
Randomized controlled trials, case-matched studies, and retrospective cohorts studies were all accepted, if reporting on ten or more RAPD.
Data extraction and management
Data were collected on customized tables. Each article was read and analyzed by at least two authors. In case of multiple Articles identified after database and manual search n=262
Abstracts assessed for eligibility n=90
Full-text articles assessed for eligibility n=13
Studies availabe for review n=7
Excluded n=6
Excluded n=77
Excluded n=172
Overlapped populations =3
Not relevant =2
(not eligible)
Few RAPD cases =1 Figure 1 Flowchart of systematic review. Abbreviation: RAPD, robot-assisted pancreaticoduodenectomy. articles from the same working group, only the most recent or the more informative publication was considered in order to avoid duplication of the data.
Results
Initial queries identified a total of 262 articles from all databases and search methods. Comparison of the retrieved titles identified 172 studies that were duplicates, thus leaving 90 abstracts for further evaluation. Additional 77 studies did not meet the inclusion criteria, and six were excluded because of various reasons (Figure 1 ), eventually leaving seven studies for the review. These studies were either retrospective cohort studies (n=4) [6] [7] [8] [9] or case-matched studies (n=3), 5, 10, 11 all published between 2010 and 2013. No randomized controlled trial was identified.
Overall, the seven studies reported data on 312 RAPDs (Table 1) . 
Current status
Our review shows that just a few hundreds of RAPDs have been reported worldwide. The fact that all RAPDs were reported in recent years, if on one hand, testifies a growing interest around this new technique, on the other, demonstrates that this operation is still being performed only by pioneers and is yet under development. Perhaps because of this, there is no agreement on patient selection criteria. Looking at the demographics of the reported series, it seems that older patients are avoided (mean patient age ranging from 60.0 to 66.4 years) and that lean patients are preferred (mean body mass index ranging from 24.2 to 27.7 kg/m 2 ). As expected, most patients undergoing PD were diagnosed with malignant tumors (224/312; 71.8%). Prevalence of malignant tumors among reviewed series ranged from 46.0% and 83.3%.
The variability of the techniques used, despite all authors employing robotic assistance at least at some stages during PD, shows also that most technical details of RAPD have to be defined yet. The hybrid approach was used in most patients (178/312; 57.0%), but most authors used a fully robotic technique (4/7; 57.1%).
Safety
Overall, there were six postoperative deaths at 30 days (6/312; 1.9%), while 137 out of 260 patients with complete information developed postoperative complications (52.7%). Postoperative pancreatic fistula (POPF) occurred in 66 patients (66/312; 21.1%). Grade C POPF was reported in eight patients (8/312; 2.5%) ( Table 2) .
It is worth noting that one intraoperative death occurred following injury to the portal vein, despite prompt conversion to open surgery. 5 In retrospective cohort studies, postoperative mortality (#30 days) ranged from 0% to 2.7% (mean 1.0%), while overall morbidity ranged from 38.0% to 62.8% (mean 52.2%). Incidence of POPF ranged from 6.3% to 38.2% (mean 24.4%). Grade C POPF occurred in five out of 182 patients with complete information (2.7%).
In case-matched studies, postoperative mortality (#30 days) ranged from 0% to 4.5% (mean 2.8%), while overall morbidity ranged from 30.0% to 50.0% (mean 38.8%). Incidence of POPF ranged from 6.7% to 35.0% (mean 19.9%). Grade C POPF occurred in three out of 94 patients with complete information (3.1%).
Figures on POPF should be read considering that most pancreases (91.2%) were reported as being soft.
The mean length of hospital stay ranged from 10 to 29 days, possibly reflecting the differences in postoperative management and policies on patient discharge from the hospitals.
The need for re-operation (#90 postoperative days) ranged from 3.0% to 10.0%.
Feasibility
RAPD was feasible in the vast majority of selected patients. Conversion to open surgery occurred between 0% and 25.0% of the patients.
In retrospective cohort studies, the mean operative time ranged from 400.5 to 597.0 minutes with an estimated mean intraoperative blood loss ranging from 220.0 mL to 633.8 mL. Figure 3 Meta-analysis of mean number of examined lymph nodes. Abbreviations: RAPD, robot-assisted pancreaticoduodenectomy; PD, pancreaticoduodenectomy; CI, confidence interval. 
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In case-matched studies, the mean operative time ranged from 444.0 to 491.5 minutes with an estimated mean intraoperative blood loss ranging from 247.0 mL to 485.0 mL (Table 3) . effectiveness Table 5 summarizes pathological parameters. Most patients (224/317; 70.6%) were operated on because of malignant tumors, though only a minority were diagnosed with ductal adenocarcinoma of the pancreas (122/317; 38.5%). The mean number of examined lymph nodes and the rate of positive surgical margins indicated that RAPD could be an appropriate operation for selected patients diagnosed with periampullary and pancreatic tumors.
Unfortunately, the issue of costs was addressed only in two manuscripts. Both reported additional costs, as compared to open surgery. Boggi et al estimated the additional costs to be 6,193 Euro per patient. 9 Similarly, Chalikonda et al estimated the additional costs of RAPD at 4,000-5,000 US dollars. 5 To further elucidate the effectiveness of RAPD, we conducted a meta-analysis on the three case-matched studies that are currently available. 5, 10, 11 Overall, there were 136 open PDs and 94 RAPDs. The following parameters were evaluated: operative time, length of hospital stay, rate of margin-free (R0) resection, number of examined lymph nodes, prevalence of malignant tumors, postoperative morbidity, incidence of POPF, and postoperative mortality.
RAPD appeared to be associated with a shorter length of hospital stay ( Figure 2 ) and a higher lymph node yield ( Figure 3) (Table 6 ).
Potential selection biases
None of the studies available was prospective and randomized. Because of the retrospective nature of examined studies, and hence the lack of prospective selection criteria, patients were operated on because of a variety of pancreatic and periampullary diseases, including both benign and malignant tumors. Crucial information, such as tumor stage, is missing. Pancreatic and periampullary tumors are indeed staged differently based on tumor type.
Case-matched studies also showed differences between comparison groups. In the study from Buchs et al, 10 the two study groups were mismatched for age (P=0.04), body mass index (P=0.01), and ASA class (P=0.01). Further, patients with different tumor types were treated, and the technique used for pancreatic anastomosis was also different between study groups (P=0.0001). In the studies by Chalikonda et al 5 and Lai et al, 11 different types of tumors were treated in the study groups.
incomplete outcome data
Again, because of the retrospective design of available studies, considerable information was missing or incomplete. Cost analysis, for instance, was available in only two studies.
Conclusion and future perspectives
The intrinsic technical difficulties of open PD have put generations of surgeons to the test, and the challenge continues nowadays. As a consequence, laparoscopic PD has remained one the last fortress of open surgery though a few gifted surgeons have safely implemented this operation in a large series of patients, [12] [13] [14] [15] even when dealing with the resection and reconstruction of the superior mesenteric/portal vein. 16 The intrinsic limitations of laparoscopy, however, make these achievements difficult to duplicate on a large scale.
The dVss is not a robot in the narrower sense of the term, since it is not capable of any autonomous or programmed action. It is rather a telepresence manipulator able to duplicate the movements of surgeon's hands at the tip of miniaturized wristed instruments, having seven degrees of freedom like the human wrist. Further, the dVss provides immersive magnified (10×-15×) 3D high-definition view, fully restoring hand-eye coordination, tremor filtration, and scaled motion. 17 These tremendous technology improvements are particularly rewarding, in comparison with standard laparoscopy, especially when delicate dissections or multiple incorporeal sutures are needed. Thus, the dVss would seem the ideal tool to make laparoscopic PD safely achievable by a larger population of pancreatic surgeons.
In this review, we have decided to consider only the articles reporting on ten or more patients to limit effect of the learning curve on reported outcomes. 18 Actually, sufficient information is not available on the number of procedures that should be carried out to complete the learning curve for RAPD. It is instead likely that most surgeons practicing RAPD are still on their learning curve or have just completed it. This could be a bias when comparing the results of RAPD Perhaps because RAPD is still in its infancy, all authors described different techniques. Even authors describing fully robotic RAPD used different techniques. This is not surprising, considering that the technique for open PD has not been standardized yet. Some of these differences, however, could be solved by the availability of the newer robotic generation, the dVss Xi. While the core technology and the basic working principles of the newer robotic system are unchanged, there are several innovations that could facilitate either the standardization of the surgical technique or a wider adoption of RAPD. The new system, indeed, permits camera hopping among ports, improves patient accessibility by the anesthesia team, increases internal work volume despite reducing the risk of inter-arm and patient collision while allowing for closer port positioning, and is expected to allow coordinated movements of the robotic arms with a specifically designed bed.
From a technical point of view, one of the surgical aspects that is not expected to change, even with the newer robotic system, is the method used to divide the pancreas neck, which is thought to be key in the development of POPF. In open surgery, a sharp division of the pancreatic neck is advised to preserve blood supply to the resection margin. Bleeding is partially prevented by placing stay sutures at the superior and inferior borders of the pancreatic neck, and arrested by individually suturing spurting bleeders while noting the position of the main pancreatic duct. 20 In RAPD, the division of the pancreatic neck employs different types of energy devices as sharp division is unpractical and a dry cut surface is preferable. All available energy devices are associated with lateral thermal spread, which induces collateral tissue injury. [21] [22] [23] When considering feasibility, RAPD appears to be feasible in most selected patients. Selection is indeed key, and there is no evidence that RAPD can be safely performed in an unselected population of patients. RAPD requires longer operative times when compared to open surgery. Reported incidence of conversion to open surgery ranged from 3.0% to 10.0%. Excluding patients who were not able to tolerate pneumoperitoneum, in most of the other patients, conversion to open surgery was caused by tumor adherence to the superior mesenteric/portal vein, difficulties in achieving complete oncologic clearance, and challenging dissection. Most of these instances are potentially predictable. It is worth noting that timely conversion to open surgery should not be viewed as treatment failure, but should be rather considered prudent surgical practice. The entire team, including the operating room personnel, should be ready to face this occurrence, especially in case of bleeding. One intraoperative death, caused by portal vein injury, was reported despite conversion to open surgery. 5 While little doubt exists that robotic assistance increases operating costs, 24 none of the available studies was specifically designed to provide full economic evaluation of RAPD. The study by Chalikonda et al 5 actually provided only a generic estimation of operating costs without describing the methodology or reporting detailed results. The study by Boggi et al estimated the operating costs of RAPD, exceeding those of open PD, considering operative and anesthesia time, robotic equipment, laparoscopic disposable devices, and the cost of the robotic system as amortized by case, including maintenance. 9 However, even this study did not provide full economic evaluation of RAPD, which includes four types of analyses: cost-minimization analysis, cost-effectiveness analysis, cost-benefit analysis, and cost-utility analysis. 24 However, whether the additional costs of robotic assistance are worth being covered cannot be answered only by economic analysis. Robotic assistance is expected to facilitate performance of some advanced operations that, like RAPD, are carried out in deep spaces and require both fine dissections and complex intracorporeal suturing. Should these advantages be confirmed, and proved to be associated with improved task quality and patient outcome, the initial investment in the robotic technology would be justified, thus significantly reducing the costs of robotic assistance.
Current results show that RAPD is safely feasible, with morbidity and mortality rates in the range reported for open PD. Perhaps when the learning curve is completed and when the results on patients with hard pancreatic remnants and dilated ducts are available, a clear advantage in comparison with open PD may become evident. At present, RAPD is safe enough to be implemented in specialized centers with sound laparoscopic background.
Based on this review, we believe that RAPD is here to stay, although nearly everything remains to be standardized and demonstrated. As robotic technology continues to improve, current limitations of RAPD are expected to become the next challenges. Eventually, RAPD will be available to a larger proportion of patients at specialized centers. We discourage surgeons not dedicated to pancreatic surgery, not Robotic Surgery: Research and Reviews
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